China Health Technology (1069) Releases Annual Results for FY2025

China Health Technology Group Holding Company Limited (1069) announced its annual results for the financial year ended 30 June 2025. Revenue increased substantially to about RMB90.2 million, compared to approximately RMB47.6 million in the prior year. Profit attributable to owners of the company reached RMB22.7 million, down from RMB200.0 million a year ago, when the Group benefited from a one-off, debt-restructuring gain.

According to the annual report, forestry management, ginseng cultivation and trading, horny goat weed cultivation, and health products trading are core operations. Forestry activities continued in Sichuan Province, with cypress logs harvested under officially approved logging quotas. The company recorded a forestry segment revenue of RMB36.6 million, supported by a total harvest volume of approximately 18,016 cubic meters of timber logs.

The ginseng segment, launched in 2022, generated revenue of around RMB39.5 million during FY2025. Of that total, RMB25.0 million was derived from purchased aged ginseng, and RMB14.5 million from self-grown cultivation. In addition, the Group introduced a health products business—chiefly ginseng gift boxes and other branded consumer items—contributing about RMB14.1 million in sales.

As of 30 June 2025, the gearing ratio dropped to around 77.3% from 92.7% in the previous year. Basic earnings per share were RMB2.75 cents (FY2024: RMB29.79 cents). The board has not proposed any dividend distribution for FY2025.

Meanwhile, the company completed share consolidations and new share placements in Hong Kong, raising further capital for general working capital. According to the annual report, total equity attributable to owners stood at RMB46.7 million, compared to RMB13.0 million a year earlier. Management will continue to monitor market conditions, manage operations in forestry and ginseng cultivation, and develop the emerging horny goat weed segment and health product line. As stated, the overall focus remains on generating stable revenue streams and maximizing shareholder returns within existing policy and regulatory guidelines.